Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Elucidating the Role of Tolerogenic Dendritic Cells in Immune Tolerance and Disease Progression in Multiple Myeloma

Mariko Ishibashi, Mika Sunakawa-Kii, Hiroki Yamaguchi, Rimpei Morita, Hideto Tamura

Blood (2023) 142 (Supplement 1): 6596.

https://doi.org/10.1182/blood-2023-179078

Published: 2023

Journal Articles

Visualization of Multiple Myeloma Mouse Model with 89 zr-Labeled Anti-CD38 Antibody By a New Imaging System; Whole-Gamma Imaging

Miwako Takahashi, Sodai Takyu, Aya Sugyo, Hitomi Sudo, Hideaki Tashima, Hidekatsu Wakizaka, Go Akamatsu, Mariko Ishibashi, Atsushi B Tsuji, Taiga Yamaya, Yoichi Imai

Blood (2022) 140 (Supplement 1): 12476–12477.

https://doi.org/10.1182/blood-2022-165050

Published: 2022

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

Journal Articles

Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

Mariko Ishibashi, PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Hiroshi Handa, MD PhD, Koiti Inokuchi, MD PhD, Hidemi Takahashi, MD PhD, Hideto Tamura, MD PhD

Blood (2018) 132 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2018-99-112322

Published: 2018

Journal Articles

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Asaka Onodera, MDPhD, Keiichi Moriya, MD PhD, Makoto Sasaki, MD PhD, Hiroshi Handa, MD PhDChief Division, Yoichi Imai, MDPhD, Norina Tanaka, MD, Junji Tanaka, MD PhD, Sakae Tanosaki, MDPhD, Shigeki Ito, MD PhD, Norio Komatsu, MD PhD, Koiti Inokuchi, MD PhD

Blood (2017) 130 (Supplement 1): 3055.

https://doi.org/10.1182/blood.V130.Suppl_1.3055.3055

Published: 2017

Journal Articles

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Toshio Asayama, MD, Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Yasuko Hamada, MD, Namiko Okuyama, MD, Asaka Onodera, MDPhD, Akiko Yamada, MD, Keiichi Moriya, MD PhD, Norio Yokose, MD PhD, Koiti Inokuchi, PhD MD

Blood (2015) 126 (23): 4117.

https://doi.org/10.1182/blood.V126.23.4117.4117

Published: 2015

Journal Articles

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Akiko Yamada, MD, Hideto Tamura, MD PhD, Mariko Ishibashi, PhD, Koiti Inokuchi, MD PhD, Makoto Sasaki, MD PhD, Yuriko Yahata, MD, Norio Komatsu, MD PhD, Atsushi Isoda, MD PhD, Morio Matsumoto, Hiroshi Handa, MD PhD, Yoichi Imai, MD PhD, Junji Tanaka, MD PhD, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Michiaki Koike, MD PhD

Blood (2014) 124 (21): 2063.

https://doi.org/10.1182/blood.V124.21.2063.2063

Published: 2014

Journal Articles

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

Blood (2014) 124 (21): 2018.

https://doi.org/10.1182/blood.V124.21.2018.2018

Published: 2014

Journal Articles

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

Yasuko Hamada, MD, Mariko Ishibashi, PhD, Toshio Asayama, MD, Namiko Okuyama, MD, Asaka Kondo, MD, PhD, Keiichi Moriya, MD, PhD, Hideya Hyodo, MD, PhD, Takehito Igarashi, MD, PhD, Hiroyuki Onose, MD, PhD, Norio Yokose, MD, PhD, Sakae Tanosaki, MD, PhD, Kazuo Shimizu, MD, PhD, Hideto Tamura, MD, PhD, Koiti Inokuchi, MD, PhD

Blood (2013) 122 (21): 4320.

https://doi.org/10.1182/blood.V122.21.4320.4320

Published: 2013

Journal Articles

CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients

Yasuko Hamada, MD, Hideto Tamura, MD, PhD, Mariko Ishibashi, PhD, Namiko Okuyama, MD, Asaka Kondo, MD, PhD, Keiichi Moriya, MD, PhD, Kiyoyuki Ogata, MD, PhD, Keiji Kakumoto, Yoshihide Miyazaki, Akira Matsuda, MD, PhD, Kaoru Tohyama, MD, PhD, Yasunori Ueda, MD, PhD, Mineo Kurokawa, MD, PhD, Hirohiko Shibayama, Nobuhiko Emi, MD, PhD, Kinuko Mitani, M.D., Ph.D., Tomoki Naoe, MD, PhD, Haruo Sugiyama, MD, PhD, Koiti Inokuchi, MD, PhD

Blood (2013) 122 (21): 2799.

https://doi.org/10.1182/blood.V122.21.2799.2799

Published: 2013

Journal Articles

B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior

Hideto Tamura, MD, PhD, Mariko Ishibashi, PhD, Taishi Yamashita, PhD, Asaka Kondo, MD, PhD, Namiko Okuyama, MD, Hideya Hyodo, MD, PhD, Yasuko Hamada, MD, Kazuo Dan, MD, PhD, Lieping Chen, MD, PhD, Kiyoyuki Ogata

Blood (2011) 118 (21): 474.

https://doi.org/10.1182/blood.V118.21.474.474

Published: 2011

NARROW

Elucidating the Role of Tolerogenic Dendritic Cells in Immune Tolerance and Disease Progression in Multiple Myeloma

Visualization of Multiple Myeloma Mouse Model with 89 zr-Labeled Anti-CD38 Antibody By a New Imaging System; Whole-Gamma Imaging

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients

B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only